Tompkins Financial Corp acquired a new stake in Haemonetics Co. (NYSE:HAE) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 560 shares of the medical instruments supplier’s stock, valued at approximately $50,000.

Other hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of Haemonetics during the fourth quarter valued at approximately $82,965,000. Eminence Capital LP lifted its position in shares of Haemonetics by 192.0% in the first quarter. Eminence Capital LP now owns 847,328 shares of the medical instruments supplier’s stock valued at $84,445,000 after acquiring an additional 557,188 shares in the last quarter. Waddell & Reed Financial Inc. acquired a new stake in shares of Haemonetics in the first quarter worth approximately $51,673,000. KAMES CAPITAL plc purchased a new stake in shares of Haemonetics during the first quarter worth approximately $49,770,000. Finally, Eaton Vance Management raised its stake in Haemonetics by 120.9% in the 1st quarter. Eaton Vance Management now owns 580,011 shares of the medical instruments supplier’s stock valued at $57,807,000 after purchasing an additional 317,460 shares during the last quarter. 99.16% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley dropped their target price on shares of Haemonetics from $138.00 to $110.00 and set an “overweight” rating for the company in a report on Wednesday, July 8th. Barrington Research downgraded shares of Haemonetics from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Raymond James lowered their target price on Haemonetics from $125.00 to $113.00 and set an “outperform” rating on the stock in a report on Wednesday, July 1st. Finally, Needham & Company LLC started coverage on Haemonetics in a report on Friday, May 29th. They issued a “buy” rating and a $132.00 price target for the company. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $130.17.

In related news, CEO Christopher Simon sold 1,008 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $100.44, for a total value of $101,243.52. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO William P. Mr. Burke sold 639 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $97.03, for a total value of $62,002.17. The disclosure for this sale can be found here. Insiders have sold a total of 127,651 shares of company stock valued at $11,404,110 over the last 90 days. 1.63% of the stock is currently owned by insiders.

Shares of NYSE:HAE opened at $87.66 on Friday. The company has a market cap of $4.41 billion, a price-to-earnings ratio of 59.63, a PEG ratio of 2.47 and a beta of 0.69. Haemonetics Co. has a fifty-two week low of $63.41 and a fifty-two week high of $140.36. The firm’s 50-day simple moving average is $89.15 and its 200-day simple moving average is $102.18. The company has a quick ratio of 1.21, a current ratio of 2.20 and a debt-to-equity ratio of 0.52.

Haemonetics (NYSE:HAE) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.69 EPS for the quarter, missing the consensus estimate of $0.73 by ($0.04). Haemonetics had a return on equity of 29.33% and a net margin of 7.74%. The company had revenue of $238.50 million for the quarter, compared to analysts’ expectations of $246.53 million. During the same quarter in the previous year, the firm posted $0.61 earnings per share. Haemonetics’s revenue for the quarter was down 4.3% on a year-over-year basis. On average, research analysts forecast that Haemonetics Co. will post 2.97 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Recommended Story: Momentum Indicator: Relative Strength Index

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.